Search results
Results from the WOW.Com Content Network
Arsphenamine, also known as Salvarsan or compound 606, is an antibiotic drug that was introduced at the beginning of the 1910s as the first effective treatment for the deadly infectious diseases syphilis, relapsing fever, and African trypanosomiasis. [2] [3] This organoarsenic compound was the first modern antimicrobial agent. [4]
1911 – Arsphenamine, also Salvarsan [1] 1912 – Neosalvarsan; 1935 – Prontosil (an oral precursor to sulfanilamide), the first sulfonamide; 1936 – Sulfanilamide; 1938 – Sulfapyridine (M&B 693) 1939 – sulfacetamide; 1940 – sulfamethizole; 1942 – benzylpenicillin, the first penicillin; 1942 – gramicidin S, the first peptide ...
Salvarsan was commercially introduced in 1910, and in 1913, a less toxic form, "Neosalvarsan" (Compound 914), was released in the market. These drugs became the principal treatments of syphilis until the arrival of penicillin and other novel antibiotics towards the middle of the 20th century. [7]
This was the first agent with a specific therapeutic effect to be created on the basis of theoretical considerations. Salvarsan proved to be amazingly effective, particularly when compared with the conventional therapy of mercury salts. Manufactured by Hoechst AG, Salvarsan became the most widely prescribed drug in the world.
The causative organism, Treponema pallidum, was first identified by Fritz Schaudinn and Erich Hoffmann in 1905 at the Charité Clinic in Berlin. [2] The first effective treatment, Salvarsan, was developed in 1910 by Sahachiro Hata in the laboratory of Paul Ehrlich. It was followed by the introduction of penicillin in 1943. [2]
The drug was marketed under the name Salvarsan and gained international acclaim as the "arsenic that saves" and as the first man-made antibiotic. [7] In the wake of their discovery, some sections of European society condemned Hata's and Ehrlich's 'magic bullet' because they believed that syphilis was a divine punishment for sin and immoral acts ...
A common antibiotic used to treat liver disease could give rise to an “almost untreatable” superbug, scientists warned in a new study.. The antibiotic, rifaximin, has enabled the global ...
Both Salvarsan and Neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. [1] This scheme is the basis for most modern pharmaceutical research.